567 related articles for article (PubMed ID: 18031501)
1. Anti-inflammatory effect of pimecrolimus in the sodium lauryl sulphate test.
Engel K; Reuter J; Seiler C; Schulte Mönting J; Jakob T; Schempp CM
J Eur Acad Dermatol Venereol; 2008 Apr; 22(4):447-50. PubMed ID: 18031501
[TBL] [Abstract][Full Text] [Related]
2. On the course of the irritant reaction after irritation with sodium lauryl sulphate.
Gloor M; Senger B; Langenauer M; Fluhr JW
Skin Res Technol; 2004 Aug; 10(3):144-8. PubMed ID: 15225263
[TBL] [Abstract][Full Text] [Related]
3. Fruit acids and sodium hydroxide in the food industry and their combined effect with sodium lauryl sulphate: controlled in vivo tandem irritation study.
Fluhr JW; Bankova L; Fuchs S; Kelterer D; Schliemann-Willers S; Norgauer J; Kleesz P; Grieshaber R; Elsner P
Br J Dermatol; 2004 Nov; 151(5):1039-48. PubMed ID: 15541082
[TBL] [Abstract][Full Text] [Related]
4. Effect of a topical corticosteroid, a retinoid and a vitamin D3 derivative on sodium dodecyl sulphate induced skin irritation.
Le TK; De Mon P; Schalkwijk J; van der Valk PG
Contact Dermatitis; 1997 Jul; 37(1):19-26. PubMed ID: 9255481
[TBL] [Abstract][Full Text] [Related]
5. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
6. Sequential application of cold and sodium lauryl sulphate decreases irritation and barrier disruption in vivo in humans.
Fluhr JW; Bornkessel A; Akengin A; Fuchs S; Norgauer J; Kleesz P; Grieshaber R; Elsner P
Br J Dermatol; 2005 Apr; 152(4):702-8. PubMed ID: 15840102
[TBL] [Abstract][Full Text] [Related]
7. Air flow at different temperatures increases sodium lauryl sulphate-induced barrier disruption and irritation in vivo.
Fluhr JW; Praessler J; Akengin A; Fuchs SM; Kleesz P; Grieshaber R; Elsner P
Br J Dermatol; 2005 Jun; 152(6):1228-34. PubMed ID: 15948986
[TBL] [Abstract][Full Text] [Related]
8. Long-term repetitive sodium lauryl sulfate-induced irritation of the skin: an in vivo study.
Branco N; Lee I; Zhai H; Maibach HI
Contact Dermatitis; 2005 Nov; 53(5):278-84. PubMed ID: 16283906
[TBL] [Abstract][Full Text] [Related]
9. Semipermeable glove membranes--effects on skin barrier repair following SLS irritation.
Bock M; Damer K; Wulfhorst B; John SM
Contact Dermatitis; 2009 Nov; 61(5):276-80. PubMed ID: 19878242
[TBL] [Abstract][Full Text] [Related]
10. O/W emulsions compromise the stratum corneum barrier and improve drug penetration.
Gloor M; Hauth A; Gehring W
Pharmazie; 2003 Oct; 58(10):709-15. PubMed ID: 14609282
[TBL] [Abstract][Full Text] [Related]
11. Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis.
Aschoff R; Schwanebeck U; Bräutigam M; Meurer M
Exp Dermatol; 2009 Jan; 18(1):24-9. PubMed ID: 18637133
[TBL] [Abstract][Full Text] [Related]
12. A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea.
Karabulut AA; Izol Serel B; Eksioglu HM
J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):729-34. PubMed ID: 18328059
[TBL] [Abstract][Full Text] [Related]
13. Differential irritant skin responses to topical retinoic acid and sodium lauryl sulphate: alone and in crossover design.
Effendy I; Weltfriend S; Patil S; Maibach HI
Br J Dermatol; 1996 Mar; 134(3):424-30. PubMed ID: 8731664
[TBL] [Abstract][Full Text] [Related]
14. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial.
Rigopoulos D; Ioannides D; Kalogeromitros D; Gregoriou S; Katsambas A
Br J Dermatol; 2004 Nov; 151(5):1071-5. PubMed ID: 15541087
[TBL] [Abstract][Full Text] [Related]
15. Treatment with pimecrolimus cream 1% clears irritant dermatitis of the periocular region, face and neck.
Mensing CO; Mensing CH; Mensing H
Int J Dermatol; 2008 Sep; 47(9):960-4. PubMed ID: 18937664
[TBL] [Abstract][Full Text] [Related]
16. The effect of damaged skin barrier induced by subclinical irritation on the sequential irritant contact dermatitis.
Yan-yu W; Xue-min W; Yi-Mei T; Ying C; Na L
Cutan Ocul Toxicol; 2011 Dec; 30(4):263-71. PubMed ID: 21774626
[TBL] [Abstract][Full Text] [Related]
17. Variation in barrier impairment and inflammation of human skin as determined by sodium lauryl sulphate penetration rate.
de Jongh CM; Jakasa I; Verberk MM; Kezic S
Br J Dermatol; 2006 Apr; 154(4):651-7. PubMed ID: 16536807
[TBL] [Abstract][Full Text] [Related]
18. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study.
Gribetz C; Ling M; Lebwohl M; Pariser D; Draelos Z; Gottlieb AB; Zaias N; Chen DM; Parneix-Spake A; Hultsch T; Menter A
J Am Acad Dermatol; 2004 Nov; 51(5):731-8. PubMed ID: 15523351
[TBL] [Abstract][Full Text] [Related]
19. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis.
Kempers S; Boguniewicz M; Carter E; Jarratt M; Pariser D; Stewart D; Stiller M; Tschen E; Chon K; Wisseh S; Abrams B
J Am Acad Dermatol; 2004 Oct; 51(4):515-25. PubMed ID: 15389185
[TBL] [Abstract][Full Text] [Related]
20. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
Hoetzenecker W; Ecker R; Kopp T; Stuetz A; Stingl G; Elbe-Bürger A
J Allergy Clin Immunol; 2005 Jun; 115(6):1276-83. PubMed ID: 15940147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
